Shares of Definium Therapeutics climbed over 30% in early trading following the announcement that its investigational drug, DT120 ODT, achieved its primary endpoint in the Phase 3 Emerge study for major depressive disorder (MDD). The company revealed that a single 100 µg dose of DT120 ODT demonstrated statistically significant and clinically meaningful improvements in depression symptoms compared to placebo at Week 6, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS). This positive outcome positions DT120 ODT as a potential new therapeutic option for MDD patients, a market with significant unmet needs.
Definium's stock, trading on Nasdaq under the ticker DFTX, reacted positively to the news. The successful Emerge trial is the first of two pivotal Phase 3 studies for DT120 ODT in MDD. The second study, Ascend, also involves a low-dose arm designed to prevent participants from accurately guessing their treatment group, a strategy the company asserts aligns with FDA guidance and was previously successful in its Phase 2b study for generalized anxiety disorder (GAD).
The company is also advancing other DT120 ODT clinical programs, with three anticipated topline readouts within the next six months. These include results from the Voyage study in GAD due in early Q3 2026, and Panorama, another GAD study with topline data expected in late Q3 2026. Definium also plans to initiate a Phase 3 Haven study in post-traumatic stress disorder (PTSD) in 2027. The positive Emerge data is crucial for the company's regulatory approach, potentially leading to an expedited New Drug Application (NDA) submission.
According to Definium's Chief Medical Officer, Daniel R. Karlin, M.D. M.A., DT120 ODT represents a potentially transformative treatment for MDD, addressing the limitations of existing therapies. He emphasized that the Ascend study aims to further build on the clinical evidence that DT120 ODT can offer a meaningfully differentiated option for a significant unmet need in psychiatry. The company, headquartered in New York, aims to become a leader in psychiatry by applying scientific rigor to psychedelics to develop accessible treatments for psychiatric and neurological disorders.
